Clinical disclaimer: This article is educational and does not constitute personal medical advice. If you take medication affected by weight change, or have type 2 diabetes, involve your clinician before making any changes. Never stop medication abruptly without clinical supervision.

Why GLP-1 medications cause gut symptoms

GLP-1 receptors are expressed throughout the gastrointestinal tract, not only in the pancreas and brain. When tirzepatide or semaglutide activates these receptors, gastric emptying slows significantly — food moves from the stomach to the small intestine more slowly. This is part of why the medications extend satiety, but it is also the mechanism behind most of the gut side effects. Nausea, constipation, reflux, and vomiting are all downstream consequences of slowed gastric emptying and altered gut motility.

Nausea: expected, manageable, and usually transient

Nausea is the most common side effect, particularly at the start of treatment and after dose increases. It reflects delayed gastric emptying — the stomach is slower to empty and the nausea signal is triggered by distension. For most patients it improves within two to four weeks as the body adapts, and it is most effectively managed by eating smaller portions, eating slowly, avoiding high-fat meals, and not lying down after eating.

Persistent severe nausea after four to six weeks on a stable dose — not just after an increase — is not expected and warrants a dose review or clinical assessment. Nausea accompanied by vomiting that prevents adequate fluid intake requires urgent review.

Constipation: common, underreported, and addressable

Constipation is the most common gastrointestinal side effect of tirzepatide specifically and affects a significant proportion of patients on higher doses of semaglutide. [1] Slowed colonic transit — a consequence of reduced gut motility — means stool spends longer in the colon, more water is absorbed, and stool becomes harder and more difficult to pass.

Management: adequate hydration (at least 2 litres per day), dietary fibre, and physical activity. If these are insufficient, osmotic laxatives (e.g. macrogol) are appropriate and safe to use alongside GLP-1 medication. Do not ignore constipation — it can worsen nausea by increasing gastric distension, and severe constipation carries a small risk of bowel obstruction in predisposed patients. If you have had bowel surgery, gastroparesis, or inflammatory bowel disease, discuss constipation management with your clinician before it becomes severe.

Reflux and heartburn: a more complex picture

Reflux and heartburn occur in a meaningful proportion of GLP-1 users. Slowed gastric emptying increases the time that stomach acid and content remain in the stomach, increasing reflux opportunity particularly when lying down. Pre-existing reflux often worsens. New reflux can emerge.

Practical steps: avoid eating within two to three hours of lying down, reduce portion sizes, and avoid high-fat meals and alcohol. These slow gastric emptying further and compound the medication's effect. If reflux is significant, a short course of a proton pump inhibitor may be appropriate — but this should be a clinician decision, not a long-term self-medicated arrangement. Read more in what good GLP-1 follow-up should include.

What resolves after stopping

Most GLP-1 gut side effects resolve after stopping the medication as gastric emptying normalises over days to weeks. Constipation typically resolves within one to two weeks. Nausea resolves quickly. Reflux may persist if the weight loss has not been maintained and the physiological drivers of reflux (intra-abdominal pressure, hiatus hernia) remain. The reversal of gut symptoms is one of the few straightforwardly positive aspects of stopping GLP-1 medication for patients who found them troublesome.

When to seek urgent help

Severe persistent abdominal pain — particularly if it radiates to the back, is constant rather than cramping, and is accompanied by nausea or vomiting — requires urgent assessment. This is the presentation of acute pancreatitis, which the MHRA has highlighted as a strengthened warning for GLP-1 and dual GLP-1/GIP agents. [2] Do not manage this at home.

Vomiting that prevents any fluid intake for more than 24 hours risks dehydration and electrolyte disturbance — contact your GP or NHS 111.

Blood in vomit or stool requires same-day medical assessment.

Severe abdominal pain with a rigid abdomen is a red flag requiring emergency attendance.

The gastroparesis concern

There has been reporting on a potential association between GLP-1 agents and gastroparesis — pathologically delayed gastric emptying. The current evidence does not establish a causal link for most patients. [3] However, if you develop severe nausea, vomiting, and upper abdominal bloating that persists beyond the typical early side-effect window, discuss this with your clinician rather than managing it independently.

For patients considering stopping GLP-1 medication, understanding the full transition — including side-effect resolution — is part of a complete GLP-1 exit plan.

FAQ

Is constipation normal on Mounjaro or Wegovy?
Yes. Constipation is one of the most common side effects of tirzepatide and occurs in a significant proportion of patients on higher-dose semaglutide. It is caused by slowed gut motility. Adequate hydration, dietary fibre, and osmotic laxatives if needed are appropriate management.
Why does Mounjaro cause nausea?
Tirzepatide slows gastric emptying — food moves through the stomach more slowly, and the nausea signal is triggered by gastric distension. Nausea is most common after dose increases and typically improves within two to four weeks. Smaller portions, slower eating, and avoiding lying down after meals all help.
When should I be worried about abdominal pain on GLP-1 medication?
Mild cramping with constipation is not concerning. Severe persistent abdominal pain — particularly radiating to the back, constant rather than cramping, accompanied by vomiting — requires urgent medical assessment. This pattern can indicate pancreatitis, which is a recognised risk with GLP-1 agents.
Does reflux get better or worse on Mounjaro?
It can go either way. Slowed gastric emptying increases reflux risk, so new or worsened reflux is common. Avoiding food within two to three hours of bed, reducing portion sizes, and limiting alcohol and high-fat meals all help. If reflux is significant, discuss whether a PPI is appropriate with your clinician.
Do GLP-1 side effects get better over time?
Most do. Nausea and vomiting are typically worst in the first month and during dose increases, then improve. Constipation may persist throughout treatment and benefits from consistent management. Most side effects resolve after stopping the medication as gastric emptying normalises.

References

  1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022.
  2. MHRA. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis. Drug Safety Update. 2026.
  3. Sodhi M et al. Risk of adverse gastrointestinal outcomes in patients taking semaglutide and other glucagon-like peptide-1 receptor agonists. JAMA. 2023.